# Cagrilintide dosage guide

> Review Cagrilintide dosage information by administration route, with source-linked dose and schedule details.

Canonical: https://pepflow.app/peptides/cagrilintide/dosage/

Compare single-agent Cagrilintide weekly injection schedules and gradual progressions, separately from combinations with semaglutide. Calculate volume and syringe units using your own vial inputs.

[Full Cagrilintide library reference](<https://pepflow.app/peptides/cagrilintide/>)

## Cagrilintide dosage chart

This summary table compares available dose amounts and schedules by administration route.

| Route | Dose | Frequency & duration |
| --- | --- | --- |
| Injectable | 0.3–4.5 mg | Once weekly · 26 weeks (monotherapy) |

## Cagrilintide dosage by administration route

### Cagrilintide injectable dosage

Single-agent subcutaneous schedules use 0.3–4.5 mg once weekly, with dose levels of 0.3, 0.6, 1.2, 2.4 or 4.5 mg over a 26-week course. Dose escalation spans up to the first 6 weeks. A lower-dose reported progression uses 0.16 mg once weekly for weeks 1–4, 0.3 mg for weeks 5–8, 0.6 mg for weeks 9–12, 1.2 mg for weeks 13–16 and 2.4 mg from week 17. This is a separate schedule from the 26-week single-agent course.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>) [\[12\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-12>)

Cagrilintide is a long-acting amylin analogue that acts on satiety signaling. Monotherapy and the semaglutide combination have distinct dose-escalation and safety requirements.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-3>)

### Frequency and timing

Use the same injection day each week.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-2>) [\[6\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-6>)

### Cycle length and breaks

Injectable: 26 weeks (monotherapy). A standard break interval between courses is not established.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>)

## Cagrilintide dosage calculator

Convert your chosen Cagrilintide amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.

For preparation terms and concentration basics, see the [reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>). Follow the arithmetic in the [concentration calculation walkthrough](<https://pepflow.app/blog/how-to-calculate-final-concentration/>).

## Cagrilintide safety and side effects

### Approval and product quality

Cagrilintide is not an FDA-approved drug.[\[5\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-5>) [\[8\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-8>) [\[10\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-10>)

### Side effects and long-term safety

Nausea and related gastrointestinal effects are important tolerability concerns. Rare events, long-term use, discontinuation effects and special-population safety remain uncertain. Hypoglycemia is also relevant in diabetes care.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-2>) [\[6\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-6>) [\[7\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-7>) [\[9\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-9>) [\[8\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-8>)

### Route-specific dosing limits

Cagrilintide remains investigational, without an approved product label. Combination exposure with semaglutide or other satiety drugs needs separate assessment. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[\[5\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-5>) [\[2\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-3>) [\[6\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-6>) [\[8\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-8>) [\[12\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-12>)

## Common Cagrilintide dosage questions

### What is the weekly single-agent Cagrilintide dosage?

Single-agent subcutaneous doses are 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly over 26 weeks, including up to 6 weeks of escalation.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>) [\[12\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-12>)

### When is Cagrilintide administered?

Use the same injection day each week.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-2>) [\[6\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-6>)

### Does Cagrilintide have a standard cycle or break interval?

Injectable: 26 weeks (monotherapy). A standard break interval between courses is not established.[\[1\]](<https://pepflow.app/peptides/cagrilintide/dosage/#source-1>)

## Sources

- [\[1\] **Once-weekly cagrilintide for weight management in people with overweight and obesity** The Lancet. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34798060/>)
- [\[2\] **Cagrilintide plus semaglutide in people with overweight or obesity: a randomised phase 1b trial** The Lancet. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/33894838/>)
- [\[3\] **Coadministered cagrilintide and semaglutide in adults with overweight or obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40544433/>)
- [\[4\] **Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression** Diabetes, obesity & metabolism, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41834765/>)
- [\[5\] **Search Drugs@FDA for cagrilintide** openFDA / U.S. Food and Drug Administration. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[6\] **REDEFINE 1 CagriSema obesity trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05567796>)
- [\[7\] **REDEFINE 2 CagriSema type 2 diabetes obesity trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05394519>)
- [\[8\] **Search Drugs@FDA for CagriSema** openFDA / U.S. Food and Drug Administration. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[9\] **Cagrilintide and semaglutide co-administration in type 2 diabetes** The Lancet. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37364590/>)
- [\[10\] **FDA's concerns with unapproved GLP-1 drugs used for weight loss** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)
- [\[11\] **Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40544432/>)
- [\[12\] **Cagrilintide — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-cagrilintide.html>)

[Full Cagrilintide library reference →](<https://pepflow.app/peptides/cagrilintide/>)

## Related

- [Cagrilintide Peptide](<https://pepflow.app/peptides/cagrilintide/>)
- [Peptide reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>)
- [How to Calculate Final Concentration: A Practical Guide](<https://pepflow.app/blog/how-to-calculate-final-concentration/>)
